Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. [electronic resource]
Producer: 20060615Description: 6688-93 p. digitalISSN:- 0027-8424
- Alleles
- Animals
- Antineoplastic Agents -- pharmacology
- B-Lymphocytes -- drug effects
- Benzamides
- Bone Marrow Transplantation
- Cyclin-Dependent Kinase Inhibitor p16
- Genes, abl
- Hematopoietic Stem Cells -- drug effects
- Humans
- Imatinib Mesylate
- Interleukin-7 -- pharmacology
- Leukemia, Lymphoid -- drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Neoplasm Transplantation
- Piperazines -- pharmacology
- Pyrimidines -- pharmacology
- Tumor Cells, Cultured
- Tumor Suppressor Protein p14ARF -- deficiency
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.